Syros Pharmaceuticals Ownership
| SYRS Stock | USD 0.26 0.01 3.70% |
Shares in Circulation | First Issued 2015-03-31 | Previous Quarter 39.3 M | Current Value 39.3 M | Avarage Shares Outstanding 9.6 M | Quarterly Volatility 12.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Syros |
Syros Stock Ownership Analysis
About 76.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.07. Syros Pharmaceuticals had not issued any dividends in recent years. The entity had 1:10 split on the 19th of September 2022. Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Syros Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. To find out more about Syros Pharmaceuticals contact Conley Chee at 617 744 1340 or learn more at https://www.syros.com.Besides selling stocks to institutional investors, Syros Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Syros Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Syros Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Syros Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Syros Pharmaceuticals are currently held by insiders. Unlike Syros Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Syros Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Syros Pharmaceuticals' insider trades
Syros Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Syros Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Syros Pharmaceuticals backward and forwards among themselves. Syros Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Syros Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Exoduspoint Capital Management, Lp | 2024-09-30 | 313 K | Exome Asset Management Llc | 2024-09-30 | 298.6 K | Blackrock Inc | 2024-06-30 | 259.2 K | Omega Fund Management Llc | 2024-09-30 | 251.3 K | Geode Capital Management, Llc | 2024-09-30 | 204.7 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 160.4 K | Perceptive Advisors Llc | 2024-09-30 | 116.8 K | Renaissance Technologies Corp | 2024-09-30 | 96.4 K | Springbok Capital Management, Llc | 2024-09-30 | 89.1 K | Bain Capital Life Sciences Investors, Llc | 2024-09-30 | 2.8 M | Adage Capital Partners Gp Llc | 2024-09-30 | 2.1 M |
Syros Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Syros Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Syros Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Syros Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Syros Pharmaceuticals Outstanding Bonds
Syros Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Syros Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Syros bonds can be classified according to their maturity, which is the date when Syros Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| SYY 315 14 DEC 51 Corp BondUS871829BR76 | View | |
| SYY 245 14 DEC 31 Corp BondUS871829BQ93 | View | |
| US871829BJ50 Corp BondUS871829BJ50 | View | |
| US871829BK24 Corp BondUS871829BK24 | View | |
| SYSCO P 445 Corp BondUS871829BH94 | View | |
| SYSCO PORATION Corp BondUS871829BN62 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.